- Review
- OPEN ACCESS
-
Histological efficacy of traditional Chinese medicine plus entecavir therapy for HBV-related liver fibrosis
-
Ting-Ting Zhu1,2,#,
-
Yun-Kai Dai2,3,#,
-
Xin Sun2,
-
Zhi-Min Zhao2,4,
-
Feng Xing2,
-
Zheng-Xin Li5,*
and
-
Cheng-Hai Liu2,4,*
Author information
Department of Traditional Chinese Medicine, The Affiliated Nanhua Hospital, University of South China, Hengyang 421001, China
Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Department of Gastroenterology, The Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Guangzhou 510130, China
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
Gongli Hospital of Shanghai Pudong New Area, Shanghai 200135, China
Correspondence to: Zheng-Xin Li, Gongli Hospital of Shanghai Pudong New Area, Shanghai 200135, China. E-mail:
Zhengxinli1990@hotmail.com; Cheng-Hai Liu, Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. E-mail:
chenghai.liu@shutcm.edu.cn
Abstract
Background/Aims
Traditional Chinese medicine (TCM) combined with antiviral therapy has been proven to be effective for liver fibrosis due to chronic hepatitis B (CHB) in clinical practice in China. However, the robust evidence is limited, and the validity of results has been controversial in the past. The current study is to evaluate the efficacy and safety of the combination therapy of TCM plus entecavir (ETV) in the management of HBV-associated liver fibrosis or cirrhosis.
Methods
Seven electronic databases were searched from inception to 10 August 2021. Primary outcome of this study was the regression of liver fibrosis; the secondary outcomes were a necro-inflammatory improvement, alanine aminotransferase (ALT), HBV DNA undetectable rate, HBeAg loss and HBeAg seroconversion. All the trials included were assessed by the Cochrane risk-of-bias tool.
Results
It showed that TCM plus ETV attenuated liver fibrosis or cirrhosis in chronic hepatitis B patients as compared to ETV monotherapy(OR = 1.65; 95% CI: 1.29~2.11; P < 0.000,1). There is no statistical difference between TCM plus ETV and ETV in histological activity index, HBV DNA undetectable rate, HBeAg loss, HBeAg seroconversion and adverse events(P<0.05).
Conclusion
The comprehensive evaluation showed that TCM combined with ETV treatment was safe for the patients with CHB, and better promoted the regression of liver fibrosis than ETV monotherapy. However, the standardized, rigorously designed, and large-scale randomized controlled trials (RCTs) were needed for further validation.
Keywords
traditional Chinese medicine,
entecavir,
HBV-related fibrosis or cirrhosis,
meta-analysis,
randomized controlled trials
|
Copyright © 2025 Authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
About this Article
Cite this article
|
Zhu TT, Dai YK, Sun X, Zhao ZM, Xing F, Li ZX, et al. Histological efficacy of traditional Chinese medicine plus entecavir therapy for HBV-related liver fibrosis. Gastroenterol & Hepatol Res. 2024;6(4):12. doi: 10.53388/ghr2024012.
|
| Copied to clipboard
|
Copy
Export to RIS
Export to EndNote
|
|
Citation copied!
|
Article History
| Received |
Revised |
Accepted |
Published |
|
|
|
|
December 30, 2024
|
DOI
http://dx.doi.org/10.53388/ghr2024012
-
Gastroenterology & Hepatology Research
-
-
eISSN 2703-173X